Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1
作者： Osamu Tomita , Kazutoshi Iijima , Takeshi Ishibashi , Tomoo Osumi , Kenichiro Kobayashi
DOI: 10.1016/J.LEUKRES.2013.11.017
关键词:
摘要: We introduced SNX2-ABL1, a novel ABL1-related chimeric transcript lacks SH3 and SH2 domains, into murine Ba/F3 cells compared their function with that of BCR-ABL1. After the expression SNX2-ABL1 proteins, acquired an ability to proliferate in IL-3-independent manner. Upon treatment both imatinib dasatinib, BCR-ABL1-expressing underwent rapid apoptosis, whereas SNX2-ABL1-expressing showed poorer sensitivity toward these TKIs could presence low dose dasatinib. Therefore, other more selective effect against this kinase should be used for patients SNX2-ABL1+ ALL.
elsevier.com
sci-hub.se 参考文章(52)
Jez Carlton, Miriam Bujny, Anna Rutherford, Pete Cullen, Sorting nexins--unifying trends and new perspectives. Traffic. ,vol. 6, pp. 75- 82 ,(2005) , 10.1111/J.1600-0854.2005.00260.X
Etienne De Braekeleer, Nathalie Douet-Guilbert, David Rowe, Nick Bown, Frédéric Morel, Christian Berthou, Claude Férec, Marc De Braekeleer, ABL1 fusion genes in hematological malignancies: a review. European Journal of Haematology. ,vol. 86, pp. 361- 371 ,(2011) , 10.1111/J.1600-0609.2011.01586.X
Kazutoshi Iijima, Hiroyuki Yamada, Masashi Miharu, Ken-Ichi Imadome, Yoshitaka Miyagawa, Shingo Akimoto, Kenichiro Kobayashi, Hajime Okita, Atsuko Nakazawa, Shigeyoshi Fujiwara, Junichiro Fujimoto, Nobutaka Kiyokawa, ZNF385B is characteristically expressed in germinal center B cells and involved in B-cell apoptosis European Journal of Immunology. ,vol. 42, pp. 3405- 3415 ,(2012) , 10.1002/EJI.201242530
Tomoko Niwa, Shinya Kimura, Tetsuo Asaki, NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor Analytical chemistry insights. ,vol. 2, pp. 93- 106 ,(2007) , 10.4137/ACI.S0
K Suryanarayan, SP Hunger, S Kohler, AJ Carroll, W Crist, MP Link, ML Cleary, Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias. Blood. ,vol. 77, pp. 324- 330 ,(1991) , 10.1182/BLOOD.V77.2.324.324
Thomas Ernst, Joannah Score, Michael Deininger, Claire Hidalgo-Curtis, Peter Lackie, William B. Ershler, John M. Goldman, Nicholas C.P. Cross, FrancisH. Grand, Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia British Journal of Haematology. ,vol. 153, pp. 43- 46 ,(2011) , 10.1111/J.1365-2141.2010.08457.X
Shaoguang Li, Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia Leukemia & Lymphoma. ,vol. 49, pp. 19- 26 ,(2008) , 10.1080/10428190701713689
M. Warmuth, S. Danhauser-Riedl, M. Hallek, Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies. Annals of Hematology. ,vol. 78, pp. 49- 64 ,(1999) , 10.1007/S002770050473
Julia Thomas, Lihui Wang, Richard E. Clark, Munir Pirmohamed, Active Transport of Imatinib into and Out of Cells: Implications for Drug Resistance Blood. ,vol. 104, pp. 3739- 3745 ,(2004) , 10.1182/BLOOD-2003-12-4276
Shugui Chen, Linda P. O'Reilly, Thomas E. Smithgall, John R. Engen, Tyrosine phosphorylation in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core. Journal of Molecular Biology. ,vol. 383, pp. 414- 423 ,(2008) , 10.1016/J.JMB.2008.08.040